Cargando…
Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006603/ https://www.ncbi.nlm.nih.gov/pubmed/35413794 http://dx.doi.org/10.1186/s12877-022-02974-z |
_version_ | 1784686700353552384 |
---|---|
author | Jia, Yu Li, Dongze Yu, Jing Liu, Yi Li, Fanghui Li, Wentao Zhang, Qin Gao, Yongli Zhang, Wei Zeng, Zhi Zeng, Rui Liao, Xiaoyang Zhao, Qian Wan, Zhi |
author_facet | Jia, Yu Li, Dongze Yu, Jing Liu, Yi Li, Fanghui Li, Wentao Zhang, Qin Gao, Yongli Zhang, Wei Zeng, Zhi Zeng, Rui Liao, Xiaoyang Zhao, Qian Wan, Zhi |
author_sort | Jia, Yu |
collection | PubMed |
description | BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for those without known CVD at baseline are associated with a higher frailty risk. METHODS: This study used data from the Atherosclerosis Risk in Communities study. Cardiac biomarkers were measured from stored plasma samples collected at Visit 2 (1991–1993). Frailty was recorded at Visit 5 (2011–2013). Cox regression models were used to determine the association of cardiac biomarkers with frailty risk. RESULTS: Overall, 360/5199 (6.9%) participants aged 55.1 ± 5.1 years developed frailty during a median follow-up of 21.7 years. The incidence of frailty was significantly higher in participants with hs-cTnT ≥14 ng/L (vs. < 14 ng/L: 17.9% vs. 6.7%) or NT-proBNP ≥300 pg/ml (vs. < 300 pg/ml: 19.7% vs. 6.8%) (all P < 0.001). Comparing higher vs. lower cut-off levels of either hs-cTnT (14 ng/l) or NT-proBNP (300 pg/ml) demonstrated a greater than two-fold higher frailty risk, with hazard ratios (HRs) of 2.13 (95% confidence interval (CI): 1.130–4.01, P = 0.020) and 2.61 (95% CI: 1.28–5.33, P = 0.008), respectively. Individuals with both elevated hs-cTnT and NT-proBNP had a higher frailty risk than those without it (HR: 4.15; 95% CI: 1.50–11.48, P = 0.006). CONCLUSIONS: High hs-cTnT and NT-proBNP levels are strongly associated with incident frailty in the community-dwelling population without known CVD. Subclinical cardiac damage (hs-cTnT) and/or wall strain (NT-proBNP) may be the key pathway of CVD patients developing frailty. Detection of hs-cTnT and NT-proBNP may help for early screening of high-risk frailty and providing individualised intervention. TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-02974-z. |
format | Online Article Text |
id | pubmed-9006603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90066032022-04-14 Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study Jia, Yu Li, Dongze Yu, Jing Liu, Yi Li, Fanghui Li, Wentao Zhang, Qin Gao, Yongli Zhang, Wei Zeng, Zhi Zeng, Rui Liao, Xiaoyang Zhao, Qian Wan, Zhi BMC Geriatr Research BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for those without known CVD at baseline are associated with a higher frailty risk. METHODS: This study used data from the Atherosclerosis Risk in Communities study. Cardiac biomarkers were measured from stored plasma samples collected at Visit 2 (1991–1993). Frailty was recorded at Visit 5 (2011–2013). Cox regression models were used to determine the association of cardiac biomarkers with frailty risk. RESULTS: Overall, 360/5199 (6.9%) participants aged 55.1 ± 5.1 years developed frailty during a median follow-up of 21.7 years. The incidence of frailty was significantly higher in participants with hs-cTnT ≥14 ng/L (vs. < 14 ng/L: 17.9% vs. 6.7%) or NT-proBNP ≥300 pg/ml (vs. < 300 pg/ml: 19.7% vs. 6.8%) (all P < 0.001). Comparing higher vs. lower cut-off levels of either hs-cTnT (14 ng/l) or NT-proBNP (300 pg/ml) demonstrated a greater than two-fold higher frailty risk, with hazard ratios (HRs) of 2.13 (95% confidence interval (CI): 1.130–4.01, P = 0.020) and 2.61 (95% CI: 1.28–5.33, P = 0.008), respectively. Individuals with both elevated hs-cTnT and NT-proBNP had a higher frailty risk than those without it (HR: 4.15; 95% CI: 1.50–11.48, P = 0.006). CONCLUSIONS: High hs-cTnT and NT-proBNP levels are strongly associated with incident frailty in the community-dwelling population without known CVD. Subclinical cardiac damage (hs-cTnT) and/or wall strain (NT-proBNP) may be the key pathway of CVD patients developing frailty. Detection of hs-cTnT and NT-proBNP may help for early screening of high-risk frailty and providing individualised intervention. TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-02974-z. BioMed Central 2022-04-12 /pmc/articles/PMC9006603/ /pubmed/35413794 http://dx.doi.org/10.1186/s12877-022-02974-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jia, Yu Li, Dongze Yu, Jing Liu, Yi Li, Fanghui Li, Wentao Zhang, Qin Gao, Yongli Zhang, Wei Zeng, Zhi Zeng, Rui Liao, Xiaoyang Zhao, Qian Wan, Zhi Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title | Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title_full | Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title_fullStr | Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title_full_unstemmed | Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title_short | Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
title_sort | subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006603/ https://www.ncbi.nlm.nih.gov/pubmed/35413794 http://dx.doi.org/10.1186/s12877-022-02974-z |
work_keys_str_mv | AT jiayu subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT lidongze subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT yujing subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT liuyi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT lifanghui subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT liwentao subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT zhangqin subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT gaoyongli subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT zhangwei subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT zengzhi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT zengrui subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT liaoxiaoyang subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT zhaoqian subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy AT wanzhi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy |